Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 7/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.40 |
| ▸ | QPCT | Q16769 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | EDNRB | P24530 | 1/20 | 0.39 |
| ▸ | EDNRA | P25101 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6039051 | 0.93 | CCR4 (0.61) | CCR4ALDH1A1KMT2AQPCTRAB9A | |
| SCHEMBL6038556 | 0.88 | CCR4 (0.54) | CCR4ALDH1A1KMT2AUTS2RRAB9A | |
| SCHEMBL6038499 | 0.85 | CCR4 (0.82) | CCR4EDNRA | |
| SCHEMBL6038859 | 0.84 | CCR4 (1.00) | CCR4EDNRA | |
| SCHEMBL6038846 | 0.84 | CCR4 (1.00) | CCR4EDNRA | |
| SCHEMBL6038838 | 0.83 | CCR4 (0.98) | CCR4EDNRA | |
| SCHEMBL6038661 | 0.82 | CCR4 (0.85) | CCR4EDNRA | |
| SCHEMBL6038552 | 0.82 | CCR4 (0.85) | CCR4KMT2AEDNRA | |
| SCHEMBL6038637 | 0.79 | CCR4 (0.68) | CCR4KMT2ASMN1; SMN2EDNRA | |
| SCHEMBL6038532 | 0.78 | CCR4 (0.79) | CCR4EDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1541563-A1 | CCR4 ANTAGONIST AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | CCR4, CCR1, CCR9 | CCR4 1/4885ALDH1A1 2902/4885KMT2A 4190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.